EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
暂无分享,去创建一个
Tim Meyer | Andrew K Burroughs | Sam Stuart | Roopinder Gillmore | A. Burroughs | T. Meyer | R. Gillmore | Ayshea Hameeduddin | Amy Kirkwood | Nick Woodward | A. Kirkwood | S. Stuart | A. Hameeduddin | N. Woodward
[1] F. Miller,et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. , 2007, AJR. American journal of roentgenology.
[2] Jordi Rimola,et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.
[3] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[4] A. Jemal,et al. Global Cancer Statistics , 2011 .
[5] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[6] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[7] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[8] B. Daniele,et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .
[9] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[10] E. Cholongitas,et al. Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.
[11] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[12] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[13] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[14] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[15] Riccardo Lencioni,et al. Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.
[16] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[17] A. Benson,et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. , 2010, JAMA.
[18] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[19] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.